Volume 3, Issue 8 (Winter 2017)                   Caspian.J.Neurol.Sci 2017, 3(8): 46-53 | Back to browse issues page


XML Print


MPH retired, Department of Family Medicine, University of Tennessee, Jackson, Tennessee; dlymanmdmph@gmail.com
Abstract:   (776 Views)

The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells.

Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells.

The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.

Full-Text [PDF 587 kb]   (339 Downloads) |   |   Full-Text (HTML)  (289 Views)  
Type of Study: Review | Subject: Special
Received: 2017/04/13 | Accepted: 2017/04/13 | Published: 2017/04/13